{"id":689073,"date":"2022-09-27T07:09:57","date_gmt":"2022-09-27T11:09:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/"},"modified":"2022-09-27T07:09:57","modified_gmt":"2022-09-27T11:09:57","slug":"aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/","title":{"rendered":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022<\/b><\/p>\n<p class=\"bwalignc\"><i>Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time<\/i><\/p>\n<p>BOSTON&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nAura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL\/CM)] will be presented at the upcoming American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022, in Chicago. The Company will also host a virtual Investor Day on Monday, October 3, 2022, from 11:30 a.m. to 1:00 p.m. Eastern Time. Aura Biosciences\u2019 executive management team will be joined by three distinguished ocular oncology thought leaders:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nCarol Shields, MD, Chief of the Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University (USA)\n<\/li>\n<li>\nIvana Kim, MD, MBA, Director of the Ocular Melanoma Center, Massachusetts Eye and Ear &amp; Associate Professor of Ophthalmology, Harvard Medical School (USA)\n<\/li>\n<li>\nMartine Jager, MD, PhD, Professor of Ophthalmology, Leiden University, (Netherlands) &amp; Past President of the International Society of Ocular Oncology and the Association for Research in Vision and Ophthalmology\n<\/li>\n<\/ul>\n<p>\nThe program will include:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nSafety and efficacy results from the ongoing Phase 2 trial evaluating suprachoroidal administration of belzupacap sarotalocan for the potential first-line treatment of patients with early-stage IL\/CM\n<\/li>\n<li>\nTwo-year visual acuity data from the retrospective matched case control study of belzupacap sarotalocan vs. plaque radiotherapy\n<\/li>\n<li>\nPreclinical data from a research collaboration with the University of Leiden (Netherlands) highlighting the possibility of using belzupacap sarotalocan in combination with immune checkpoint inhibitors to treat primary and distant lesions by an abscopal effect\n<\/li>\n<\/ul>\n<p><b>Details for the Presentation at AAO:<\/b><\/p>\n<p><b>Title:<\/b> A Phase 2 Trial of AU-011, a First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration\n<\/p>\n<p><b>Presenter: <\/b>Ivana K. Kim, MD, Massachusetts Eye and Ear\n<\/p>\n<p><b>Session #: <\/b>PA028\n<\/p>\n<p><b>Location #: <\/b>S405\n<\/p>\n<p><b>Date\/Time: <\/b>Sunday, October 2, 2022, at 9:45 a.m. CST\n<\/p>\n<p>\nThe paper will be available <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Faurabiosciences.com%2Fvdc-platform%2Fscientific-presentations%2F&amp;esheet=52926893&amp;newsitemid=20220927005381&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=1f9581fc0750f3e51d09bb2b690611de\">here<\/a> following the presentation.\n<\/p>\n<p><b>Details for the Virtual Investor Day:<\/b><\/p>\n<p>\nTo access the virtual Investor Day, please dial (888) 660-6585 (U.S. and Canada) or (929) 203-0858 (international) at least 10 minutes prior to the start time and refer to conference ID 9748492. A live video webcast will be available in the Investor section of the Company\u2019s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fir.aurabiosciences.com%2Fevents-and-presentations&amp;esheet=52926893&amp;newsitemid=20220927005381&amp;lan=en-US&amp;anchor=https%3A%2F%2Fir.aurabiosciences.com%2Fevents-and-presentations&amp;index=2&amp;md5=18352a0fbe3f2f3bf20a96addb579913\">https:\/\/ir.aurabiosciences.com\/events-and-presentations<\/a>. A webcast replay will also be available on the corporate website at the conclusion of the call.\n<\/p>\n<p><b>About Aura Biosciences<\/b><\/p>\n<p>\nAura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura\u2019s lead VDC candidate, belzupacap sarotalocan (AU-011), consists of a virus-like particle conjugated with an anti-cancer agent. Belzupacap sarotalocan is designed to selectively target and destroy cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. Belzupacap sarotalocan is currently in development for ocular cancers, and Aura plans to pursue development of belzupacap sarotalocan across its ocular oncology franchise including for the treatment of patients with choroidal metastasis. In addition, leveraging Aura\u2019s technology platform, Aura is developing belzupacap sarotalocan more broadly across multiple cancers, including in patients with non-muscle invasive bladder cancer (NMIBC). Aura is headquartered in Boston, MA.\n<\/p>\n<p>\nFor more information, visit aurabiosciences.com, or follow us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FAuraBiosciences&amp;esheet=52926893&amp;newsitemid=20220927005381&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=152e92504022ccc83b8a41442ea4b771\">Twitter<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faurabiosciences%2F&amp;esheet=52926893&amp;newsitemid=20220927005381&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=4&amp;md5=0a1271911a46c10305af99bb1040e4d2\">LinkedIn<\/a>.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20220927005381\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220927005381\/en\/<\/a><\/span><\/p>\n<p><b>Investor and Media:<\/b><\/p>\n<p>\nAlex Dasalla<br \/>\n<br \/>Head of Investor Relations and Corporate Communications<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:adasalla@aurabiosciences.com\">adasalla@aurabiosciences.com<\/a><\/p>\n<p>\nArgot Partners<br \/>\n<br \/>Matthew DeYoung<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:aura@argotpartners.coma\">aura@argotpartners.coma<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research FDA Clinical Trials Biotechnology Pharmaceutical Health Optical Science Oncology Other Science<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time BOSTON&#8211;(BUSINESS WIRE)&#8211; Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL\/CM)] will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-689073","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time BOSTON&#8211;(BUSINESS WIRE)&#8211; Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL\/CM)] will be &hellip; Continue reading &quot;Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T11:09:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022\",\"datePublished\":\"2022-09-27T11:09:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/\"},\"wordCount\":681,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/\",\"name\":\"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-09-27T11:09:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/","og_locale":"en_US","og_type":"article","og_title":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk","og_description":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 Company to Host Virtual Investor Day with Ocular Oncology Experts on Monday, October 3, 2022, at 11:30 a.m. Eastern Time BOSTON&#8211;(BUSINESS WIRE)&#8211; Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that data from the ongoing Phase 2 trial evaluating the safety and efficacy of suprachoroidal (SC) administration using its first VDC product candidate, belzupacap sarotalocan (AU-011), for the first-line treatment of patients with early-stage choroidal melanoma [indeterminate lesions and small choroidal melanoma (IL\/CM)] will be &hellip; Continue reading \"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-27T11:09:57+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022","datePublished":"2022-09-27T11:09:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/"},"wordCount":681,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/","name":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2022-09-27T11:09:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220927005381r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-to-present-ongoing-phase-2-data-evaluating-suprachoroidal-administration-of-belzupacap-sarotalocan-au-011-for-the-first-line-treatment-of-patients-with-early-stage-choroidal-melanom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689073","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=689073"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/689073\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=689073"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=689073"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=689073"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}